European Pharmaceutical Review

AUGUST 25, 2022

This strategy has failed to gain a foothold in the past as the patient’s immune system interferes, destroying the unprotected oncolytic viruses. 7 Studies also sought to modify oncolytic viruses with additional genes that more efficiently recruit the patient’s immune system to target tumour cells. suppressing activity.

Immunization 101

Immunization Chemotherapy Packaging 101

pharmaphorum

NOVEMBER 4, 2021

While still preliminary, the experience with the two patients back up Talaris’ hope that giving a one-shot dose of FCR001 the day after an organ transplant could stimulate immune tolerance in the recipient, and avoid the side effects of current drug treatments such as infections, heart disease, and some forms of cancer.

Immunization 98

Immunization 98

Pharmacy Times

OCTOBER 3, 2023

In addition to the annual flu vaccines, COVID-19 boosters and RSV vaccines present new opportunities for pharmacists to advise patients.

Immunization 65

Immunization Vaccines 65

pharmaphorum

AUGUST 2, 2022

In May, another amyloid targeting drug for Alzheimer’s disease – AC Immune and Roche’s crenezumab – missed the mark in another clinical trial and looked destined for the scrap heap like so many drugs in the class before it. The post AC Immune tries to resurrect crenezumab with new data delve appeared first on.

Immunization 52

Immunization 52

Pharma Mirror

FEBRUARY 18, 2021

A novel approach for ensuring the virtually unlimited production of QS-21, the ‘Gold Standard’ adjuvant for improving vaccine efficacy, will be the subject of an upcoming presentation at the BIO CEO & Investor Digital Conference, starting February 16.

Immunization 52

Immunization Vaccines 52

STAT

FEBRUARY 29, 2024

The vaccine effectiveness estimates, which showed unusually robust protection of children against influenza B viruses but more modest protection of people aged 65 and older against influenza A viruses, were presented Wednesday at a meeting of the CDC’s expert vaccine panel, the Advisory Committee on Immunization Practices.

Vaccines 114

Vaccines Immunization 114

STAT

FEBRUARY 29, 2024

At a meeting Thursday of the Advisory Committee on Immunization Practices, vaccine safety experts from the two agencies presented data that showed what appears to be an elevated rate of GBS, as the condition is called, among people who got the Pfizer vaccine, although there were also cases detected among people who got the GSK product.

Vaccines 143

Vaccines Immunization 143

STAT

APRIL 10, 2024

But as researchers from different companies and academic institutions presented promising early data at the American Association for Cancer Research annual meeting in San Diego this week, experts said there’s a collective feeling of turning a corner. SAN DIEGO — Cancer vaccines have traveled a potholed road over the last decade.

Vaccines 145

Vaccines Immunization 145

Pharmaceutical Technology

JUNE 6, 2023

PF-06835375 is a biologic commercialized by Pfizer, with a leading Phase II program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV).

Immunization 40

Immunization Hospitals 40

pharmaphorum

APRIL 4, 2022

In particular, the findings suggest that disruption to innate immunity – the first line of defence against pathogens – as well as overly aggressive activity of white blood cells in the central nervous system called microglia. ” The post Study uncovers new Alzheimer’s genes, links to immune disruption appeared first on.

Immunization 52

Immunization 52

Pharmafile

APRIL 18, 2023

read more

Immunization 40

Immunization Vaccines 40

STAT

DECEMBER 10, 2022

NEW ORLEANS — Researchers had hoped in recent years that a protein called GPRC5D might offer a new way to get the immune system to hunt down and destroy multiple myeloma cells. Now, the results of a Phase 2 study on a bispecific antibody targeting this protein offers confirmation.

Immunization 119

Immunization 119

Pharmafile

APRIL 3, 2023

aVaxziPen, a biotech company focusing on the development of a novel needle-free vaccine delivery platform, has announced that it will present data at the World Vaccine Congress (WVC) in Washington, US. read more

Vaccines 72

Vaccines Immunization 72

Pharmaceutical Technology

FEBRUARY 24, 2023

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The post Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Retatrutide? The net profit of the company was US$6,244.8

Pharmaceutical Companies 45

Pharmaceutical Companies Pharmaceutical Companies Immunization 45

STAT

FEBRUARY 22, 2023

The data were presented Wednesday to the Advisory Committee on Immunization Policy, which advises the Centers for Disease Control and Prevention. Read the rest…

Immunization 98

Immunization Hospitals Vaccines 98

Pharmaceutical Technology

FEBRUARY 18, 2023

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The post Risk adjusted net present value: What is the current valuation of Novartis’s Gevokizumab? appeared first on Pharmaceutical Technology.

Generic Medicine 40

Generic Medicine Immunization 40

European Pharmaceutical Review

MARCH 26, 2024

Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition.

Vaccines 94

Vaccines Immunization 94

Roots Analysis

DECEMBER 11, 2022

Presently, over 170 companies are engaged in the development of more than 970 early and late-stage T-cell therapies, worldwide. The post CAR-T Cell Therapies: Advancing Immune Cells to Treat Cancer appeared first on Blog. CAR-T Cell Therapies – Current Market Landscape.

Immunization 40

Immunization 40

European Pharmaceutical Review

DECEMBER 12, 2023

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.

Immunization 110

Immunization Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 110

Pharmafile

OCTOBER 25, 2023

GSK announced positive results from its phase 3 trial which assessed the immune response and safety of Arexvy, its respiratory syncytial virus (RSV) vaccine, adjuvanted, in adults aged 50 to 59 including those at an increased risk of RSV lower respiratory tract disease (LRTD) due to underlying conditions.

Vaccines 59

Vaccines Immunization 59

European Pharmaceutical Review

SEPTEMBER 20, 2023

Results of a Phase I/II study has revealed that a booster dose of a novel, self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine induces a robust, broadly cross-reactive, and durable immune response in adults. All three vaccines induced robust neutralising immune response against the D614G variant at Day 29.

Vaccines 95

Vaccines Immunization 95

European Pharmaceutical Review

DECEMBER 15, 2023

The companies previously presented data from KEYNOTE-942/mRNA-4157-P201, with a follow-up of approximately two years, at the American Association for Cancer Research (AACR) Annual Meeting, and the American Society of Clinical Oncology (ASCO) Annual Meeting. The most common adverse events were fatigue, injection site pain and chills.

Vaccines 100

Vaccines Research Laboratories Immunization 100

Pharmaceutical Technology

SEPTEMBER 14, 2022

Before TIL infusion, the patient undergoes lymphodepletion, which reduces the proportion of myeloid immune suppressive cells and creates space for the incoming lymphocytes. The high level of neoantigens in melanoma makes this the ideal setting for TIL therapy, with tumours often containing multiple clones of tumour-reactive immune cells.

Immunization 98

Immunization 98

Pharmaceutical Technology

MAY 26, 2023

was powered by the advent of immune-checkpoint inhibitors, added Chalk. Checkpoint modulators, cytokines and oncolytic viruses are also considered as part of the overall immune-oncology field. Apart from providing an overview of the current pipeline, the webinar also presented the findings from a GlobalData survey.

Immunization 105

Immunization Vaccines Compounding Insurance 105

PharmaShots

APRIL 17, 2023

The OS results were consistent across subgroups & the results are being shared with regulatory authorities globally The safety profile was consistent with prior reported studies, grade 3-4 TRAEs (70% vs 69%); TRAEs led to death (2% vs 1%) with no new safety signals, grade 3-4 immune-mediated AEs (7% vs 4%); patient experienced immune-mediated AEs (..)

Immunization 40

Immunization FDA 40

European Pharmaceutical Review

SEPTEMBER 1, 2023

Global mRNA-based oncology therapy market At present, the pharmaceutical industry is still awaiting the first regulatory approval of an mRNA-based oncology therapy. If successful, this trial will mark the first time an mRNA cancer vaccine and an immune checkpoint inhibitor have shown improved recurrence-free survival rates.

Immunization 94

Immunization Vaccines 94

European Pharmaceutical Review

JANUARY 30, 2024

Pembrolizumab targets a “checkpoint” pathway that is key in enabling cancer cells to avoid being destroyed by the immune system. As a result, the immunotherapy drug supports the immune system’s T cells fight tumours, the researchers highlighted. We showed pembrolizumab extends survival. It does not only delay recurrence.”

Immunization 92

Immunization 92

NF2 BioSolutions

JULY 25, 2023

As we are part of an inflammation-focussed group , we are not only interested in the Schwann cells (the tumour cells that grow and multiply to form the main bulk of the tumour) but also the body’s immune cells that invade into the tumour itself. are they close to each other, to the blood vessels, to a specific type e.g

Immunization 98

Immunization Communication 98

The Checkup by Singlecare

APRIL 1, 2024

When you come into contact with an allergen, the immune system may mistake it for a harmful substance. An overreactive immune system then creates chemicals called histamines, which trigger symptoms of allergies like excess mucus, swelling, and itchiness, according to the National Library of Medicine.

Immunization 105

Immunization Mayo Clinic 105

pharmaphorum

MAY 3, 2022

Early clinical outcomes and novel TCE design modifications have fueled the development and clinical advancement of over 65 bispecific T-cell engagers (TCEs), which are presently in Phase I and Phase II investigations since the Cell Engager Series began.

Immunization 52

Immunization 52

Pharmafile

APRIL 17, 2023

read more

Immunization 40

Immunization 40

Pharmaceutical Technology

MARCH 31, 2023

Data presented by the European Centre for Disease Prevention and Control shows that cumulative vaccination uptake has stalled, with only a few thousand vaccine doses administered in March 2023 , across the European Union/European Economic Area. The NHS will be using Covid-19 vaccines manufactured by Pfizer, Moderna and Sanofi.

Vaccines 110

Vaccines Immunization 110

European Pharmaceutical Review

NOVEMBER 25, 2022

Certain RNA methyltransferases regulate RNA sensing and innate immune activation and represent novel immune-regulatory targets. We anticipate presenting results from our Phase I study in 2023.” In addition, STC-15 has shown efficacy in leukaemia models via mechanisms including inhibition of leukaemia stem cell function.

Immunization 88

Immunization 88

European Pharmaceutical Review

SEPTEMBER 13, 2022

The current standard of care for patients with recurrent, unresectable or metastatic disease is immune checkpoint inhibitor monotherapy targeting anti-programmed death receptor 1 (anti-PD-1) and programmed death ligand 1 (PD-L1), but only about half of patients respond to this therapy.

Immunization 76

Immunization 76

Pharma Times

APRIL 17, 2023

Efti’s targeting activation of antigen-presenting cells delivers an adaptive immunity to fight cancer

Immunization 42

Immunization 42

Pharmafile

MARCH 28, 2023

Published date: 28/03/2023 Summary: - Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpoints - VTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen (HBsAg) - Results will be presented at the upcoming European Association for the Study of the Liver (EASL) Congress (..)

Immunization 52

Immunization 52

Pharmaceutical Technology

JUNE 6, 2023

Our pan-coronavirus vaccine candidate presents a potential universal solution to the evolving nature of SARS-CoV-2 and potentially future coronaviruses by targeting mucosal immunity at the source, being readily deployable through faster manufacturing and exhibiting lower barriers for storage and transportation.”

Vaccines 92

Vaccines Immunization 92